City File: High hopes

Saturday 26 September 1992 23:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

MEDEVA, the pharmaceuticals group, has high hopes for methylphenidate, its amphetamine drug used to treat hyperactive children. Increased demand has given Medeva greater leverage in negotiating production quotas with the US authorities. The drug, which is highly cash-generative with gross margins in excess of 80 per cent, is thought to be taking market share from Ciba Geigy, the only other manufacturer.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

City File: High hopes

Join our commenting forum

Thank you for registering